Kathleen M. Schmainda1,2, Devyani Bedekar1,2,
Scott D. Rand1,2, Jennifer Connelly, 23, Mark Malkin,
23
1Radiology, Medical College of
Wisconsin, Milwaukee, WI, United States; 2Translational Brain
Tumor Research Program, Medical College of Wisconsin, Milwaukee, WI, United
States; 3Neurology, Medical College of Wisconsin, Milwaukee, WI,
United States
The
prognosis for patients diagnosed with brain tumors has been dismal. Now there
is hope with improved time to progression and survival noted for patients
treated with anti-angiogenic drugs such as bevacizumab. Yet, many questions remain regarding the
appropriate selection of patients most likely to respond. These questions are
important from both a clinical and economic perspective and therefore speak
to the need for ways to efficiently and reliably predict response. Here we demonstrate the potential of
DSC-measures of rCBV, obtained just prior to treatment with bevacizumab, to
predict outcomes in patients with both new and recurrent GBM.